首页 > 最新文献

Revista de gastroenterologia de Mexico (English)最新文献

英文 中文
Relationship between platelet indices in acute cholecystitis: A case-control study 急性胆囊炎中血小板指数之间的关系:病例对照研究
Pub Date : 2024-04-01 DOI: 10.1016/j.rgmxen.2023.04.012
S. Özdemir , İ. Altunok , A. Özkan , M.M. İslam , A. Algın , S.E. Eroğlu , G. Aksel

Introduction and aims

We aimed to investigate changes in initial platelet indices in patients arriving at the emergency department with acute cholecystitis.

Material and methods

A retrospective case-control study was conducted at a tertiary care teaching hospital. Demographics, comorbidities, laboratory data, length of hospital stay, and mortality data for the acute cholecystitis group were retrospectively obtained from the hospital digital database. Platelet count, mean platelet volume, plateletcrit, platelet distribution width, and platelet mass index were collected.

Results

A total of 553 patients with acute cholecystitis were the study cases, and 541 hospital employees were the study controls. According to the results of the multivariate analysis of the platelet indices studied, only mean platelet volume and platelet distribution width showed significant differences between the two groups (adjusted odds ratio: 2, 95% confidence interval: 1.4−2.7, p < 0.001 and adjusted odds ratio: 5.88, 95% confidence interval: 2.44−14.4, p < 0.001, respectively). The multivariate regression model created had an area under the curve of 0.969 in the prediction of acute cholecystitis (accuracy: 0.917, sensitivity: 89%, and specificity: 94.5%).

Conclusion

The study results indicate that the initial mean platelet volume and platelet distribution width were independent predictors of acute cholecystitis.

材料与方法 在一家三级甲等教学医院开展了一项回顾性病例对照研究。急性胆囊炎组的人口统计学、合并症、实验室数据、住院时间和死亡率数据均从医院数字数据库中回顾性获得。研究还收集了血小板计数、血小板平均体积、血小板crit、血小板分布宽度和血小板质量指数。根据所研究的血小板指数的多变量分析结果,只有平均血小板体积和血小板分布宽度在两组之间有显著差异(调整后的几率比:2,95% 置信区间:1.4-2.7,p <0.001;调整后的几率比:5.88,95% 置信区间:2.44-14.4,p <0.001)。建立的多变量回归模型在预测急性胆囊炎方面的曲线下面积为 0.969(准确性:0.917,敏感性:89%,特异性:94.5%)。
{"title":"Relationship between platelet indices in acute cholecystitis: A case-control study","authors":"S. Özdemir ,&nbsp;İ. Altunok ,&nbsp;A. Özkan ,&nbsp;M.M. İslam ,&nbsp;A. Algın ,&nbsp;S.E. Eroğlu ,&nbsp;G. Aksel","doi":"10.1016/j.rgmxen.2023.04.012","DOIUrl":"10.1016/j.rgmxen.2023.04.012","url":null,"abstract":"<div><h3>Introduction and aims</h3><p>We aimed to investigate changes in initial platelet indices in patients arriving at the emergency department with acute cholecystitis.</p></div><div><h3>Material and methods</h3><p>A retrospective case-control study was conducted at a tertiary care teaching hospital. Demographics, comorbidities, laboratory data, length of hospital stay, and mortality data for the acute cholecystitis group were retrospectively obtained from the hospital digital database. Platelet count, mean platelet volume, plateletcrit, platelet distribution width, and platelet mass index were collected.</p></div><div><h3>Results</h3><p>A total of 553 patients with acute cholecystitis were the study cases, and 541 hospital employees were the study controls. According to the results of the multivariate analysis of the platelet indices studied, only mean platelet volume and platelet distribution width showed significant differences between the two groups (adjusted odds ratio: 2, 95% confidence interval: 1.4−2.7, p &lt; 0.001 and adjusted odds ratio: 5.88, 95% confidence interval: 2.44−14.4, p &lt; 0.001, respectively). The multivariate regression model created had an area under the curve of 0.969 in the prediction of acute cholecystitis (accuracy: 0.917, sensitivity: 89%, and specificity: 94.5%).</p></div><div><h3>Conclusion</h3><p>The study results indicate that the initial mean platelet volume and platelet distribution width were independent predictors of acute cholecystitis.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 232-236"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000701/pdfft?md5=f958187e9abb48f2043d2c42e27170e2&pid=1-s2.0-S2255534X23000701-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9758272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
YouTube® in Spanish as a source of information for patients with inflammatory bowel disease 将西班牙语 YouTube® 作为炎症性肠病患者的信息来源
Pub Date : 2024-04-01 DOI: 10.1016/j.rgmxen.2022.09.002
C.E. Lombo-Moreno , O.M. Muñoz-Velandia , D.G. Fernández-Ávila , J.E. Barahona-Correa , V. López-Ramírez , A. Rodriguez-Varon

Introduction and aim

The majority of patients with inflammatory bowel disease (IBD) seek information about their disease on the Internet. The reliability, comprehensiveness, and quality of said information in Spanish has not previously been studied.

Materials and methods

An analytic observational study was conducted that included YouTube® videos on IBD available in Spanish, describing general characteristics, engagement, and sources. Standard tools for evaluating reliability (DISCERN), comprehensiveness, and overall quality (Global Quality Score, GQS) were employed.

Results

One hundred videos were included. Eighty-eight videos consisted of information produced by healthcare professionals (group 1) and 12 included patient opinions (group 2). There were no differences in the median scores for reliability (DISCERN 3 vs 3, p = 0.554) or comprehensiveness (3 vs 2.5, p = 0.768) between the two groups, but there was greater overall quality in the group 2 videos (GQS 3 vs 4, p = 0.007). Reliability was higher for the videos produced by professional organizations (DISCERN 4; IQR 3–4), when compared with healthcare information websites and for-profit agencies (DISCERN 3; IQR 2.5–3.5) (p < 0.001), but the videos with healthcare information website and for-profit sources had a higher quality score (GQS 3 vs 4, p < 0.001). Comprehensiveness scores were similar.

Conclusion

The majority of YouTube® videos in Spanish on IBD have good reliability, comprehensiveness, and quality. Reliability was greater for the videos produced by professional organizations, whereas quality was higher for those created from healthcare information websites and for-profit agencies.

引言和目的大多数炎症性肠病(IBD)患者都在互联网上寻求有关其疾病的信息。材料与方法我们开展了一项分析性观察研究,其中包括 YouTube® 上有关 IBD 的西班牙语视频,描述了这些视频的一般特征、参与度和来源。研究采用了评估可靠性(DISCERN)、全面性和总体质量(全球质量评分,GQS)的标准工具。其中 88 个视频由医护人员制作(第 1 组),12 个视频包含患者意见(第 2 组)。两组视频在可靠性(DISCERN 3 vs 3,p = 0.554)和全面性(3 vs 2.5,p = 0.768)的中位数得分上没有差异,但第二组视频的整体质量更高(GQS 3 vs 4,p = 0.007)。与医疗保健信息网站和营利机构(DISCERN 3;IQR 2.5-3.5)相比,专业组织制作的视频(DISCERN 4;IQR 3-4)可靠性更高(p <0.001),但医疗保健信息网站和营利机构制作的视频质量得分更高(GQS 3 vs 4,p <0.001)。结论大多数 YouTube® 西班牙语 IBD 视频具有良好的可靠性、全面性和质量。专业组织制作的视频可靠性更高,而医疗保健信息网站和营利机构制作的视频质量更高。
{"title":"YouTube® in Spanish as a source of information for patients with inflammatory bowel disease","authors":"C.E. Lombo-Moreno ,&nbsp;O.M. Muñoz-Velandia ,&nbsp;D.G. Fernández-Ávila ,&nbsp;J.E. Barahona-Correa ,&nbsp;V. López-Ramírez ,&nbsp;A. Rodriguez-Varon","doi":"10.1016/j.rgmxen.2022.09.002","DOIUrl":"10.1016/j.rgmxen.2022.09.002","url":null,"abstract":"<div><h3>Introduction and aim</h3><p>The majority of patients with inflammatory bowel disease (IBD) seek information about their disease on the Internet. The reliability, comprehensiveness, and quality of said information in Spanish has not previously been studied.</p></div><div><h3>Materials and methods</h3><p>An analytic observational study was conducted that included YouTube® videos on IBD available in Spanish, describing general characteristics, engagement, and sources. Standard tools for evaluating reliability (DISCERN), comprehensiveness, and overall quality (Global Quality Score, GQS) were employed.</p></div><div><h3>Results</h3><p>One hundred videos were included. Eighty-eight videos consisted of information produced by healthcare professionals (group 1) and 12 included patient opinions (group 2). There were no differences in the median scores for reliability (DISCERN 3 vs 3, <em>p</em> = 0.554) or comprehensiveness (3 vs 2.5, <em>p</em> = 0.768) between the two groups, but there was greater overall quality in the group 2 videos (GQS 3 vs 4, <em>p</em> = 0.007). Reliability was higher for the videos produced by professional organizations (DISCERN 4; IQR 3–4), when compared with healthcare information websites and for-profit agencies (DISCERN 3; IQR 2.5–3.5) (<em>p</em> &lt; 0.001), but the videos with healthcare information website and for-profit sources had a higher quality score (GQS 3 vs 4, <em>p</em> &lt; 0.001). Comprehensiveness scores were similar.</p></div><div><h3>Conclusion</h3><p>The majority of YouTube® videos in Spanish on IBD have good reliability, comprehensiveness, and quality. Reliability was greater for the videos produced by professional organizations, whereas quality was higher for those created from healthcare information websites and for-profit agencies.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 176-185"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000427/pdfft?md5=122201f376a5112623f9060acbcca115&pid=1-s2.0-S2255534X23000427-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9442948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
YouTube® as a source of information for patients with gastrointestinal disease 将 YouTube® 作为胃肠道疾病患者的信息来源
Pub Date : 2024-04-01 DOI: 10.1016/j.rgmxen.2023.05.007
J. Bandera Quijano
{"title":"YouTube® as a source of information for patients with gastrointestinal disease","authors":"J. Bandera Quijano","doi":"10.1016/j.rgmxen.2023.05.007","DOIUrl":"10.1016/j.rgmxen.2023.05.007","url":null,"abstract":"","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 2","pages":"Pages 173-175"},"PeriodicalIF":0.0,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000646/pdfft?md5=8dcc6620b4083701e8c067f00d486cf4&pid=1-s2.0-S2255534X23000646-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9568808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abdominal ultrasound findings in adult patients with cystic fibrosis 囊性纤维化成年患者的腹部超声波检查结果。
Pub Date : 2024-01-01 DOI: 10.1016/j.rgmxen.2022.07.002
E. Baran , M.V. D’Ascenzo , J.D. Bosia , P. Montaña

Introduction and aims

Cystic fibrosis (CF) is a genetic disease whose gastrointestinal compromise mainly involves the pancreas, bile ducts, and liver. Our aim was to analyze abdominal ultrasound findings.

Methods

A retrospective, descriptive study was conducted on adults (patients ≥ 16 years of age) diagnosed with CF, within the time frame of 2006-2019. Clinical and genetic parameters, body mass index, forced expiratory volume in one second, pancreatic insufficiency, CF-related diabetes, cirrhosis secondary to CF, and abdominal ultrasound images were analyzed.

Results

Seventy patients, 39 of whom were men (55.8%), had a mean age of 27 years and a mean body mass index of 21.3 ± 2.8 kg/m2 (r: 17-30.9). Forty-seven (67.1%) presented with pancreatic insufficiency, 6 (8.5%) with cirrhosis secondary to CF, and 21 (30%) had CF-related diabetes. Median forced expiratory volume in one second was 47% and the F508del mutation was found in 56.1%. Images of the pancreas: no pathologic findings in 49 (70%), increased echogenicity in 18 (25.7%), and cysts in 3 (4.3%). Gallbladder images: microgallbladder in 3 (4.2%), biliary sludge in 2 (2.8%), gallstones in 7 (10%), and a history of cholecystectomy in 4 (5.8%). Liver and spleen images: no pathologic findings in 47 (67.2%), homogeneous hepatomegaly with splenomegaly in 2 (2.8%), a heterogeneous pattern of the parenchyma in 11 (15.8%), increased echogenicity in 4 (5.7%), and heterogeneous echo patterns, lobulated liver contour, and splenomegaly in 6 (8.5%).

Conclusion

Abdominal ultrasound is a safe, low-cost technique that enables the identification of some degree of chronic liver and pancreatic diseases, improving the approach and follow-up decisions in adult patients with CF.

导言和目的:囊性纤维化(CF)是一种遗传性疾病,其胃肠道损害主要涉及胰腺、胆管和肝脏。我们的目的是分析腹部超声波检查结果:我们对 2006-2019 年期间确诊为 CF 的成人(患者年龄≥ 16 岁)进行了一项回顾性、描述性研究。研究分析了临床和遗传参数、体重指数、一秒用力呼气量、胰腺功能不全、CF 相关糖尿病、继发于 CF 的肝硬化以及腹部超声图像:70名患者中有39名男性(55.8%),平均年龄为27岁,平均体重指数为21.3 ± 2.8 kg/m2(r:17-30.9)。47人(67.1%)患有胰腺功能不全,6人(8.5%)继发于CF肝硬化,21人(30%)患有与CF相关的糖尿病。一秒用力呼气量中位数为 47%,56.1% 发现 F508del 基因突变。胰腺图像:49 例(70%)无病理发现,18 例(25.7%)回声增强,3 例(4.3%)有囊肿。胆囊图像:3 例(4.2%)为微小胆囊,2 例(2.8%)为胆汁淤积,7 例(10%)为胆结石,4 例(5.8%)有胆囊切除术史。肝脏和脾脏图像:47 例(67.2%)无病理发现,2 例(2.8%)同型肝脏肿大伴脾脏肿大,11 例(15.8%)实质形态异型,4 例(5.7%)回声增强,6 例(8.5%)回声形态异型、肝脏轮廓分叶状和脾脏肿大:结论:腹部超声是一种安全、低成本的技术,能够识别某种程度的慢性肝脏和胰腺疾病,从而改善成年 CF 患者的治疗方法和随访决策。
{"title":"Abdominal ultrasound findings in adult patients with cystic fibrosis","authors":"E. Baran ,&nbsp;M.V. D’Ascenzo ,&nbsp;J.D. Bosia ,&nbsp;P. Montaña","doi":"10.1016/j.rgmxen.2022.07.002","DOIUrl":"10.1016/j.rgmxen.2022.07.002","url":null,"abstract":"<div><h3>Introduction and aims</h3><p>Cystic fibrosis (CF) is a genetic disease whose gastrointestinal compromise mainly involves the pancreas, bile ducts, and liver. Our aim was to analyze abdominal ultrasound findings.</p></div><div><h3>Methods</h3><p>A retrospective, descriptive study was conducted on adults (patients ≥ 16 years of age) diagnosed with CF, within the time frame of 2006-2019. Clinical and genetic parameters, body mass index, forced expiratory volume in one second, pancreatic insufficiency, CF-related diabetes, cirrhosis secondary to CF, and abdominal ultrasound images were analyzed.</p></div><div><h3>Results</h3><p>Seventy patients, 39 of whom were men (55.8%), had a mean age of 27 years and a mean body mass index of 21.3 ± 2.8 kg/m<sup>2</sup> (r: 17-30.9). Forty-seven (67.1%) presented with pancreatic insufficiency, 6 (8.5%) with cirrhosis secondary to CF, and 21 (30%) had CF-related diabetes. Median forced expiratory volume in one second was 47% and the F508del mutation was found in 56.1%. Images of the pancreas: no pathologic findings in 49 (70%), increased echogenicity in 18 (25.7%), and cysts in 3 (4.3%). Gallbladder images: microgallbladder in 3 (4.2%), biliary sludge in 2 (2.8%), gallstones in 7 (10%), and a history of cholecystectomy in 4 (5.8%). Liver and spleen images: no pathologic findings in 47 (67.2%), homogeneous hepatomegaly with splenomegaly in 2 (2.8%), a heterogeneous pattern of the parenchyma in 11 (15.8%), increased echogenicity in 4 (5.7%), and heterogeneous echo patterns, lobulated liver contour, and splenomegaly in 6 (8.5%).</p></div><div><h3>Conclusion</h3><p>Abdominal ultrasound is a safe, low-cost technique that enables the identification of some degree of chronic liver and pancreatic diseases, improving the approach and follow-up decisions in adult patients with CF.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 19-24"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X22000883/pdfft?md5=76aaf7e16143cb2d9e41736d9fb55a5f&pid=1-s2.0-S2255534X22000883-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40539226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guidelines for the management of coagulation disorders in patients with cirrhosis 肝硬化患者凝血功能障碍管理指南
Pub Date : 2024-01-01 DOI: 10.1016/j.rgmxen.2023.08.008
I. Aiza-Haddad , L.E. Cisneros-Garza , O. Morales-Gutiérrez , R. Malé-Velázquez , M.T. Rizo-Robles , R. Alvarado-Reyes , L.A. Barrientos-Quintanilla , F. Betancourt-Sánchez , E. Cerda-Reyes , R. Contreras-Omaña , M.B. Dehesa-Violante , N.C. Flores-García , D. Gómez-Almaguer , M.F. Higuera-de la Tijera , M.A. Lira-Pedrin , J.E. Lira-Vera , H. Manzano-Cortés , D.E. Meléndez-Mena , M.R. Muñoz-Ramírez , J.L. Pérez-Hernández , J.F. Sánchez-Ávila

Coagulation management in the patient with cirrhosis has undergone a significant transformation since the beginning of this century, with the concept of a rebalancing between procoagulant and anticoagulant factors. The paradigm that patients with cirrhosis have a greater bleeding tendency has changed, as a result of this rebalancing. In addition, it has brought to light the presence of complications related to thrombotic events in this group of patients.

These guidelines detail aspects related to pathophysiologic mechanisms that intervene in the maintenance of hemostasis in the patient with cirrhosis, the relevance of portal hypertension, mechanical factors for the development of bleeding, modifications in the hepatic synthesis of coagulation factors, and the changes in the reticuloendothelial system in acute hepatic decompensation and acute-on-chronic liver failure. They address new aspects related to the hemorrhagic complications in patients with cirrhosis, considering the risk for bleeding during diagnostic or therapeutic procedures, as well as the usefulness of different tools for diagnosing coagulation and recommendations on the pharmacologic treatment and blood-product transfusion in the context of hemorrhage. These guidelines also update the knowledge regarding hypercoagulability in the patient with cirrhosis, as well as the efficacy and safety of treatment with the different anticoagulation regimens. Lastly, they provide recommendations on coagulation management in the context of acute-on-chronic liver failure, acute liver decompensation, and specific aspects related to the patient undergoing liver transplantation.

自本世纪初以来,随着促凝因子和抗凝因子之间重新平衡的概念的提出,肝硬化患者的凝血管理发生了重大转变。由于这种重新平衡,肝硬化患者出血倾向更强的模式也发生了改变。这些指南详细阐述了肝硬化患者维持止血的病理生理机制、门静脉高压的相关性、出血发生的机械因素、肝脏合成凝血因子的变化以及急性肝功能失代偿和急性-慢性肝功能衰竭时网状内皮系统的变化。这些指南涉及与肝硬化患者出血性并发症相关的新方面,考虑了诊断或治疗过程中的出血风险、不同凝血诊断工具的实用性以及出血情况下的药物治疗和血制品输注建议。这些指南还更新了有关肝硬化患者高凝状态的知识,以及不同抗凝方案的疗效和安全性。最后,指南还就急性慢性肝功能衰竭、急性肝功能失代偿以及肝移植患者相关的特定方面的凝血管理提出了建议。
{"title":"Guidelines for the management of coagulation disorders in patients with cirrhosis","authors":"I. Aiza-Haddad ,&nbsp;L.E. Cisneros-Garza ,&nbsp;O. Morales-Gutiérrez ,&nbsp;R. Malé-Velázquez ,&nbsp;M.T. Rizo-Robles ,&nbsp;R. Alvarado-Reyes ,&nbsp;L.A. Barrientos-Quintanilla ,&nbsp;F. Betancourt-Sánchez ,&nbsp;E. Cerda-Reyes ,&nbsp;R. Contreras-Omaña ,&nbsp;M.B. Dehesa-Violante ,&nbsp;N.C. Flores-García ,&nbsp;D. Gómez-Almaguer ,&nbsp;M.F. Higuera-de la Tijera ,&nbsp;M.A. Lira-Pedrin ,&nbsp;J.E. Lira-Vera ,&nbsp;H. Manzano-Cortés ,&nbsp;D.E. Meléndez-Mena ,&nbsp;M.R. Muñoz-Ramírez ,&nbsp;J.L. Pérez-Hernández ,&nbsp;J.F. Sánchez-Ávila","doi":"10.1016/j.rgmxen.2023.08.008","DOIUrl":"https://doi.org/10.1016/j.rgmxen.2023.08.008","url":null,"abstract":"<div><p>Coagulation management in the patient with cirrhosis has undergone a significant transformation since the beginning of this century, with the concept of a rebalancing between procoagulant and anticoagulant factors. The paradigm that patients with cirrhosis have a greater bleeding tendency has changed, as a result of this rebalancing. In addition, it has brought to light the presence of complications related to thrombotic events in this group of patients.</p><p>These guidelines detail aspects related to pathophysiologic mechanisms that intervene in the maintenance of hemostasis in the patient with cirrhosis, the relevance of portal hypertension, mechanical factors for the development of bleeding, modifications in the hepatic synthesis of coagulation factors, and the changes in the reticuloendothelial system in acute hepatic decompensation and acute-on-chronic liver failure. They address new aspects related to the hemorrhagic complications in patients with cirrhosis, considering the risk for bleeding during diagnostic or therapeutic procedures, as well as the usefulness of different tools for diagnosing coagulation and recommendations on the pharmacologic treatment and blood-product transfusion in the context of hemorrhage. These guidelines also update the knowledge regarding hypercoagulability in the patient with cirrhosis, as well as the efficacy and safety of treatment with the different anticoagulation regimens. Lastly, they provide recommendations on coagulation management in the context of acute-on-chronic liver failure, acute liver decompensation, and specific aspects related to the patient undergoing liver transplantation.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 144-162"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000124/pdfft?md5=c96d61fbcb22480ab06061e16a1fb62d&pid=1-s2.0-S2255534X24000124-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease 除 TPMT 和 NUDT15 外,ITPA 多态性并不能预测炎症性肠病硫嘌呤诱导的全血细胞减少症的额外风险。
Pub Date : 2024-01-01 DOI: 10.1016/j.rgmxen.2021.11.017
A. Jena , N. Grover , P. Bhatia , M. Singh , D. Lad , K.K. Prasad , H. Singh , U. Dutta , V. Sharma

Introduction and aim

Thiopurine-related leukopenia is associated with polymorphisms in the thiopurine methyltransferase (TPMT) and nucleoside diphosphate-linked moiety X type motif 15 (NUDT15) genes. However, those polymorphisms explain only a fraction of thiopurine-related leukopenia. Our aim was to study the role of an inosine triphosphate pyrophosphatase (ITPA) polymorphism in patients with inflammatory bowel disease (IBD) and thiopurine-related leukopenia that was unexplained by the TPMT and NUDT15 polymorphisms.

Material and methods

We enrolled consecutive IBD patients on thiopurines (azathioprine or 6-mercaptopurine) from January 2019–March 2020, at a tertiary care center in North India. The presence of the ITPA (C.94C > A) polymorphism was evaluated in all patients, along with its association with thiopurine-related leukopenia.

Results

Of the 33 patients (from a total of 119 patients) that developed leukopenia, 8 had the TPMT (n = 1) or NUDT15 (n = 7) polymorphism. Of the remaining 111 patients, their mean age was 36.36 ± 13.54 years and 57 (51.3%) were males. Twenty-five (21.01%) had unexplained leukopenia. The ITPA polymorphism was detected in 4 (16%) patients in the unexplained leukopenia group and 24 (27.9%) patients in the non-leukopenia group (p = 0.228). The odds ratio for predicting leukopenia with the ITPA polymorphism was 0.4921 (95% CI 0.1520–1.5830, p = 0.234).

Conclusion

The ITPA (C.94C > A) polymorphism was frequently detected in the study population but was not predictive for leukopenia in patients with IBD on thiopurine therapy.

简介和目的:硫嘌呤相关性白细胞减少症与硫嘌呤甲基转移酶(TPMT)和核苷二磷酸连接分子 X 型杂环 15(NUDT15)基因的多态性有关。然而,这些多态性只能解释部分与硫嘌呤相关的白细胞减少症。我们的目的是研究三磷酸肌苷焦磷酸酶(ITPA)多态性在炎症性肠病(IBD)和硫嘌呤相关性白细胞减少症患者中的作用:2019年1月至2020年3月,我们在印度北部的一家三级医疗中心连续招募了使用硫嘌呤类药物(硫唑嘌呤或6-巯基嘌呤)的IBD患者。对所有患者的 ITPA(C.94C > A)多态性及其与硫嘌呤相关白细胞减少症的关系进行了评估:结果:在出现白细胞减少症的 33 名患者(共 119 名患者)中,有 8 人存在 TPMT(1 人)或 NUDT15(7 人)多态性。其余 111 名患者的平均年龄为(36.36 ± 13.54)岁,其中 57 人(51.3%)为男性。25人(21.01%)患有原因不明的白细胞减少症。不明原因白细胞减少症组有 4 名(16%)患者检测到 ITPA 多态性,非白细胞减少症组有 24 名(27.9%)患者检测到 ITPA 多态性(P = 0.228)。通过 ITPA 多态性预测白细胞减少症的几率比为 0.4921 (95% CI 0.1520-1.5830, p = 0.234):ITPA(C.94C > A)多态性在研究人群中被频繁检测到,但并不能预测接受硫嘌呤治疗的 IBD 患者的白细胞减少症。
{"title":"ITPA polymorphisms do not predict additional risk beyond TPMT and NUDT15 for thiopurine-induced cytopenia in inflammatory bowel disease","authors":"A. Jena ,&nbsp;N. Grover ,&nbsp;P. Bhatia ,&nbsp;M. Singh ,&nbsp;D. Lad ,&nbsp;K.K. Prasad ,&nbsp;H. Singh ,&nbsp;U. Dutta ,&nbsp;V. Sharma","doi":"10.1016/j.rgmxen.2021.11.017","DOIUrl":"10.1016/j.rgmxen.2021.11.017","url":null,"abstract":"<div><h3>Introduction and aim</h3><p>Thiopurine-related leukopenia is associated with polymorphisms in the thiopurine methyltransferase (TPMT) and nucleoside diphosphate-linked moiety X type motif 15 (NUDT15) genes. However, those polymorphisms explain only a fraction of thiopurine-related leukopenia. Our aim was to study the role of an inosine triphosphate pyrophosphatase (ITPA) polymorphism in patients with inflammatory bowel disease (IBD) and thiopurine-related leukopenia that was unexplained by the TPMT and NUDT15 polymorphisms.</p></div><div><h3>Material and methods</h3><p>We enrolled consecutive IBD patients on thiopurines (azathioprine or 6-mercaptopurine) from January 2019–March 2020, at a tertiary care center in North India. The presence of the ITPA (C.94C &gt; A) polymorphism was evaluated in all patients, along with its association with thiopurine-related leukopenia.</p></div><div><h3>Results</h3><p>Of the 33 patients (from a total of 119 patients) that developed leukopenia, 8 had the TPMT (n = 1) or NUDT15 (n = 7) polymorphism. Of the remaining 111 patients, their mean age was 36.36 ± 13.54 years and 57 (51.3%) were males. Twenty-five (21.01%) had unexplained leukopenia. The ITPA polymorphism was detected in 4 (16%) patients in the unexplained leukopenia group and 24 (27.9%) patients in the non-leukopenia group (p = 0.228). The odds ratio for predicting leukopenia with the ITPA polymorphism was 0.4921 (95% CI 0.1520–1.5830, p = 0.234).</p></div><div><h3>Conclusion</h3><p>The ITPA (C.94C &gt; A) polymorphism was frequently detected in the study population but was not predictive for leukopenia in patients with IBD on thiopurine therapy.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 25-30"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000063/pdfft?md5=3a7f13d141c58a93a6984dac6dd2af48&pid=1-s2.0-S2255534X23000063-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10625603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología 诊断和治疗胃食管反流病的良好临床实践建议。墨西哥胃肠病学会专家评论
Pub Date : 2024-01-01 DOI: 10.1016/j.rgmxen.2023.12.002
M.A. Valdovinos Díaz , M. Amieva-Balmori , R. Carmona-Sánchez , E. Coss-Adame , O. Gómez-Escudero , M. González-Martínez , F. Huerta-Iga , E. Morel-Cerda , J.M. Remes-Troche , J.L. Tamayo-de la Cuesta , G. Torres-Villalobos , L.R. Valdovinos-García , G. Vázquez-Elizondo , A.S. Villar-Chávez , J.A. Arenas-Martínez

Introduction

Gastroesophageal reflux disease (GERD) is very prevalent in the general population, with a broad spectrum of clinical manifestations, requiring accurate diagnosis and treatment.

Aim

The aim of this expert review is to establish good clinical practice recommendations for the diagnosis and personalized treatment of GERD.

Methods

The good clinical practice recommendations were produced by a group of experts in GERD, members of the Asociación Mexicana de Gastroenterología (AMG), after carrying out an extensive review of the published literature and discussing each recommendation at a face-to-face meeting. This document does not aim to be a clinical practice guideline with the methodology such a document requires.

Results

Fifteen experts on GERD formulated 27 good clinical practice recommendations for recognizing the symptoms and complications of GERD, the rational use of diagnostic tests and medical treatment, the identification and management of refractory GERD, the overlap with functional disorders, endoscopic and surgical treatment, and GERD in the pregnant woman, older adult, and the obese patient.

Conclusions

An accurate diagnosis of GERD is currently possible, enabling the prescription of a personalized treatment in patients with this condition. The goal of the good clinical practice recommendations by the group of experts from the AMG presented in this document is to aid both the general practitioner and specialist in the process of accurate diagnosis and treatment, in the patient with GERD.

导言胃食管反流病(GERD)在普通人群中非常普遍,临床表现范围广泛,需要准确的诊断和治疗。本专家综述旨在为胃食管反流病的诊断和个性化治疗制定良好的临床实践建议。方法胃食管反流病专家小组(墨西哥胃肠病协会(AMG)成员)对已发表的文献进行了广泛的综述,并在面对面的会议上对每项建议进行了讨论,然后制定了良好的临床实践建议。结果十五位胃食管反流病专家制定了 27 项良好临床实践建议,涉及胃食管反流病症状和并发症的识别、诊断测试和药物治疗的合理使用、难治性胃食管反流病的识别和管理、与功能性疾病的重叠、内镜和手术治疗,以及孕妇、老年人和肥胖患者的胃食管反流病。结论目前可以对胃食管反流病进行准确诊断,从而为该病患者开出个性化治疗处方。AMG 专家小组在本文件中提出的良好临床实践建议旨在帮助全科医生和专科医生对胃食管反流病患者进行准确诊断和治疗。
{"title":"Good clinical practice recommendations for the diagnosis and treatment of gastroesophageal reflux disease. An expert review from the Asociación Mexicana de Gastroenterología","authors":"M.A. Valdovinos Díaz ,&nbsp;M. Amieva-Balmori ,&nbsp;R. Carmona-Sánchez ,&nbsp;E. Coss-Adame ,&nbsp;O. Gómez-Escudero ,&nbsp;M. González-Martínez ,&nbsp;F. Huerta-Iga ,&nbsp;E. Morel-Cerda ,&nbsp;J.M. Remes-Troche ,&nbsp;J.L. Tamayo-de la Cuesta ,&nbsp;G. Torres-Villalobos ,&nbsp;L.R. Valdovinos-García ,&nbsp;G. Vázquez-Elizondo ,&nbsp;A.S. Villar-Chávez ,&nbsp;J.A. Arenas-Martínez","doi":"10.1016/j.rgmxen.2023.12.002","DOIUrl":"https://doi.org/10.1016/j.rgmxen.2023.12.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Gastroesophageal reflux disease (GERD) is very prevalent in the general population, with a broad spectrum of clinical manifestations, requiring accurate diagnosis and treatment.</p></div><div><h3>Aim</h3><p>The aim of this expert review is to establish good clinical practice recommendations for the diagnosis and personalized treatment of GERD.</p></div><div><h3>Methods</h3><p>The good clinical practice recommendations were produced by a group of experts in GERD, members of the <em>Asociación Mexicana de Gastroenterología</em> (<em>AMG</em>), after carrying out an extensive review of the published literature and discussing each recommendation at a face-to-face meeting. This document does not aim to be a clinical practice guideline with the methodology such a document requires.</p></div><div><h3>Results</h3><p>Fifteen experts on GERD formulated 27 good clinical practice recommendations for recognizing the symptoms and complications of GERD, the rational use of diagnostic tests and medical treatment, the identification and management of refractory GERD, the overlap with functional disorders, endoscopic and surgical treatment, and GERD in the pregnant woman, older adult, and the obese patient.</p></div><div><h3>Conclusions</h3><p>An accurate diagnosis of GERD is currently possible, enabling the prescription of a personalized treatment in patients with this condition. The goal of the good clinical practice recommendations by the group of experts from the <em>AMG</em> presented in this document is to aid both the general practitioner and specialist in the process of accurate diagnosis and treatment, in the patient with GERD.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 121-143"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000112/pdfft?md5=3b5a5d1707194092fe42e4e167b15dea&pid=1-s2.0-S2255534X24000112-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation: A phase 3, randomized, placebo-controlled study lubiprostone治疗慢性特发性便秘的疗效和安全性:一项3期随机安慰剂对照研究
Pub Date : 2024-01-01 DOI: 10.1016/j.rgmxen.2023.05.006
E. Coss-Adame , J.M. Remes-Troche , R. Flores Rendón , J.L. Tamayo de la Cuesta , M.A. Valdovinos Díaz

Introduction

Chronic idiopathic constipation (CIC) negatively impacts quality of life and increases healthcare costs. Lubiprostone stimulates the secretion of intestinal fluid, in turn facilitating the passage of stools and alleviating associated symptoms. Lubiprostone has been available in Mexico since 2018, but its clinical efficacy has not been studied in a Mexican population.

Aim

To evaluate the efficacy of lubiprostone, assessed by changes in spontaneous bowel movement (SBM) frequency after one week of treatment with 24 μg oral lubiprostone (b.i.d.), as well as its safety, over four weeks of treatment.

Study

Randomized, double-blind, placebo-controlled study on 211 adults with CIC in Mexico.

Results

The increase in SBM frequency, after one week of treatment, was significantly higher in the lubiprostone group than in the placebo group (mean: 4.9 [SD: 4.45] vs. 3.0 [3.14], p = 0.020). Secondary efficacy endpoints revealed a significantly higher proportion of SBM frequency/week in the lubiprostone group at weeks 2, 3, and 4. There was a better response within 24 h after the first dose with lubiprostone vs. placebo (60.0% vs. 41.5%; OR: 2.08, CI95%: [1.19, 3.62], p = 0.009) and the lubiprostone group also had significant improvement, with respect to straining, stool consistency, abdominal bloating, and Satisfaction Index. The main adverse events were gastrointestinal disorders in 13 (12.4%) lubiprostone-treated subjects and 4 (3.8%) control subjects.

Conclusions

Our data confirm the efficacy and safety of lubiprostone for the treatment of CIC in a Mexican population. Lubiprostone treatment induces relief from the most bothersome symptoms associated with constipation.

导言:慢性特发性便秘(CIC)对生活质量造成了负面影响,并增加了医疗成本。鲁比前列酮可刺激肠液分泌,进而促进粪便排出并缓解相关症状。目的 通过口服 24 μg 路比前列通(b.i.d. )治疗一周后自发性排便(SBM)频率的变化来评估路比前列通的疗效,以及其安全性、耐药性和耐药性。结果治疗一周后,鲁比前列酮组的自发性排便次数明显高于安慰剂组(平均值:4.9 [SD: 4.45] vs. 3.0 [3.14],P = 0.020)。次要疗效终点显示,在第 2、3 和 4 周,鲁比前列酮组的 SBM 频率/周比例明显更高。与安慰剂相比,鲁比前列酮组在首次用药后 24 小时内的反应更好(60.0% 对 41.5%;OR:2.08,CI95%:[1.19, 3.62],p = 0.009),而且鲁比前列酮组在拉稀、大便稠度、腹胀和满意度指数方面也有显著改善。结论:我们的数据证实了路比前列通在墨西哥人群中治疗 CIC 的有效性和安全性。我们的数据证实了路比前列酮治疗 CIC 在墨西哥人群中的有效性和安全性。
{"title":"Efficacy and safety of lubiprostone for the treatment of chronic idiopathic constipation: A phase 3, randomized, placebo-controlled study","authors":"E. Coss-Adame ,&nbsp;J.M. Remes-Troche ,&nbsp;R. Flores Rendón ,&nbsp;J.L. Tamayo de la Cuesta ,&nbsp;M.A. Valdovinos Díaz","doi":"10.1016/j.rgmxen.2023.05.006","DOIUrl":"10.1016/j.rgmxen.2023.05.006","url":null,"abstract":"<div><h3>Introduction</h3><p>Chronic idiopathic constipation (CIC) negatively impacts quality of life and increases healthcare costs. Lubiprostone stimulates the secretion of intestinal fluid, in turn facilitating the passage of stools and alleviating associated symptoms. Lubiprostone has been available in Mexico since 2018, but its clinical efficacy has not been studied in a Mexican population.</p></div><div><h3>Aim</h3><p>To evaluate the efficacy of lubiprostone, assessed by changes in spontaneous bowel movement (SBM) frequency after one week of treatment with 24 μg oral lubiprostone (b.i.d.), as well as its safety, over four weeks of treatment.</p></div><div><h3>Study</h3><p>Randomized, double-blind, placebo-controlled study on 211 adults with CIC in Mexico.</p></div><div><h3>Results</h3><p>The increase in SBM frequency, after one week of treatment, was significantly higher in the lubiprostone group than in the placebo group (mean: 4.9 [SD: 4.45] <em>vs.</em> 3.0 [3.14], <em>p</em> = 0.020). Secondary efficacy endpoints revealed a significantly higher proportion of SBM frequency/week in the lubiprostone group at weeks 2, 3, and 4. There was a better response within 24 h after the first dose with lubiprostone <em>vs.</em> placebo (60.0% <em>vs.</em> 41.5%; OR: 2.08, CI95%: [1.19, 3.62], <em>p</em> = 0.009) and the lubiprostone group also had significant improvement, with respect to straining, stool consistency, abdominal bloating, and Satisfaction Index. The main adverse events were gastrointestinal disorders in 13 (12.4%) lubiprostone-treated subjects and 4 (3.8%) control subjects.</p></div><div><h3>Conclusions</h3><p>Our data confirm the efficacy and safety of lubiprostone for the treatment of CIC in a Mexican population. Lubiprostone treatment induces relief from the most bothersome symptoms associated with constipation.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 70-79"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X23000622/pdfft?md5=7e45b855aeec9385f219176096c6fac8&pid=1-s2.0-S2255534X23000622-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9522517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Peristomal varices: Another cause of bleeding in patients with portal hypertension 肛门周围静脉曲张:门静脉高压症患者出血的另一个原因。
Pub Date : 2024-01-01 DOI: 10.1016/j.rgmxen.2024.01.001
E. Jasso-Baltazar , J. Ruiz-Manriquez , L.E. Zamora-Nava
{"title":"Peristomal varices: Another cause of bleeding in patients with portal hypertension","authors":"E. Jasso-Baltazar ,&nbsp;J. Ruiz-Manriquez ,&nbsp;L.E. Zamora-Nava","doi":"10.1016/j.rgmxen.2024.01.001","DOIUrl":"10.1016/j.rgmxen.2024.01.001","url":null,"abstract":"","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 165-166"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X24000094/pdfft?md5=049d8c866e53c942710a3e5de010846f&pid=1-s2.0-S2255534X24000094-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140195276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of chronic diarrhea in patients newly diagnosed with HIV infection through the FilmArray® gastrointestinal panel 通过 FilmArray® 胃肠道样本对新诊断出的 HIV 感染者的慢性腹泻进行评估。
Pub Date : 2024-01-01 DOI: 10.1016/j.rgmxen.2023.02.002
R. Montalvo-Otivo , P. Vilcapoma , A. Murillo , C. Mathey , A. Olivera , G. Veliz , D. Estrella

Introduction

The treatment and diagnosis of chronic diarrhea in the immunocompromised patient depends on the ability to rapidly detect the etiologic agents.

Aims

Our aim was to evaluate the results of the FilmArray® gastrointestinal panel in patients newly diagnosed with HIV infection that presented with chronic diarrhea.

Material and methods

Utilizing nonprobability consecutive convenience sampling, 24 patients were included that underwent molecular testing for the simultaneous detection of 22 pathogens.

Results

In 24 HIV-infected patients with chronic diarrhea, enteropathogen bacteria were detected in 69% of the cases, parasites in 18%, and viruses in 13%. Enteropathogenic Escherichia coli and enteroaggregative Escherichia coli were the main bacteria identified, Giardia lamblia was found in 25%, and norovirus was the most frequent viral agent. The median number of infectious agents per patient was three (range of 0 to 7). The biologic agents not identified through the FilmArray® method were tuberculosis and fungi.

Conclusions

Several infectious agents were simultaneously detected through the FilmArray® gastrointestinal panel in patients with HIV infection and chronic diarrhea.

简介:免疫功能低下患者慢性腹泻的治疗和诊断取决于快速检测病原体的能力:免疫功能低下患者慢性腹泻的治疗和诊断取决于快速检测病原体的能力。目的:我们的目的是评估FilmArray®胃肠道检测试剂盒对新诊断为慢性腹泻的HIV感染患者的检测结果:采用非概率连续方便抽样法,对 24 名患者进行分子检测,同时检测 22 种病原体:结果:在 24 名感染艾滋病毒的慢性腹泻患者中,69% 的病例检测到肠道病原菌,18% 的病例检测到寄生虫,13% 的病例检测到病毒。肠致病性大肠杆菌和肠聚集性大肠杆菌是主要的细菌,25%的病例中发现了蓝氏贾第鞭毛虫,诺如病毒是最常见的病毒病原体。每名患者感染病原体的中位数为 3 种(0 至 7 种不等)。未通过 FilmArray® 方法确定的生物病原体是结核菌和真菌:结论:FilmArray® 胃肠道检测板可同时检测出艾滋病病毒感染者和慢性腹泻患者体内的多种感染病原体。
{"title":"Evaluation of chronic diarrhea in patients newly diagnosed with HIV infection through the FilmArray® gastrointestinal panel","authors":"R. Montalvo-Otivo ,&nbsp;P. Vilcapoma ,&nbsp;A. Murillo ,&nbsp;C. Mathey ,&nbsp;A. Olivera ,&nbsp;G. Veliz ,&nbsp;D. Estrella","doi":"10.1016/j.rgmxen.2023.02.002","DOIUrl":"10.1016/j.rgmxen.2023.02.002","url":null,"abstract":"<div><h3>Introduction</h3><p>The treatment and diagnosis of chronic diarrhea in the immunocompromised patient depends on the ability to rapidly detect the etiologic agents.</p></div><div><h3>Aims</h3><p>Our aim was to evaluate the results of the FilmArray® gastrointestinal panel in patients newly diagnosed with HIV infection that presented with chronic diarrhea.</p></div><div><h3>Material and methods</h3><p>Utilizing nonprobability consecutive convenience sampling, 24 patients were included that underwent molecular testing for the simultaneous detection of 22 pathogens.</p></div><div><h3>Results</h3><p>In 24 HIV-infected patients with chronic diarrhea, enteropathogen bacteria were detected in 69% of the cases, parasites in 18%, and viruses in 13%. Enteropathogenic <em>Escherichia coli</em> and enteroaggregative <em>Escherichia coli</em> were the main bacteria identified, <em>Giardia lamblia</em> was found in 25%, and norovirus was the most frequent viral agent. The median number of infectious agents per patient was three (range of 0 to 7). The biologic agents not identified through the FilmArray® method were tuberculosis and fungi.</p></div><div><h3>Conclusions</h3><p>Several infectious agents were simultaneously detected through the FilmArray® gastrointestinal panel in patients with HIV infection and chronic diarrhea.</p></div>","PeriodicalId":74705,"journal":{"name":"Revista de gastroenterologia de Mexico (English)","volume":"89 1","pages":"Pages 80-88"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2255534X2300021X/pdfft?md5=55e58bfb82adf6c42ce53f4552dd8dfc&pid=1-s2.0-S2255534X2300021X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9085405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Revista de gastroenterologia de Mexico (English)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1